NCT01477749 - Sipuleucel-T Manufacturing Demonstration Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Cancer of ProstateCancer of the ProstateNeoplasms, ProstateNeoplasms, ProstaticProstate CancerProstate NeoplasmsProstatic Cancer

Interventions

BIOLOGICAL

sipuleucel-T

Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.

Trial Locations (4)

94805

Department of Cancer Medicine and Genitourinary Oncology Group Institut Gustave Roussy (IGR) Département de médicine, Vaillant

A-1100

Ludwig Boltzmann-Institute for Applied Cancer Research, Vienna

6525 GA

Radboud University Nijmegen; UMC St Radboud Hospital; Faculteit der Medische Wetenschappen, Urologie, Nijmegen

EC1M 6BQ

Barts Cancer Institute - a Cancer Research UK Centre of Excellence, Queen Mary University of London, London